Congestive Heart Failure (CHF)

Publishing Date : July, 2015
Report Code : HCCV105
Price:
Single license $3,600
Site license $5,400
Global license $7,200


Congestive Heart Failure (CHF) Pipeline Analysis gives comprehensive insight on the various drugs being developed for the treatment of CHF. The report covers all the drugs being developed in various development phases (Discovery to Phase 2 clinical). The pipeline focuses on disease modification and includes pharmacologic drugs, gene therapy, stem cell therapy and RNA-based therapeutics, but excludes symptom relief drugs like diuretics, acute treatments, angiotensins or thrombin inhibitors etc. The report also covers some of the hot targets in research for CHF treatments.

This report enables Pharmaceutical /Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative opportunities in the CHF Drug market. The report also provide strategic insights on medicines that are likely to have an impact on CHF treatment space and potentially alter standards of care in CHF in the foreseeable future.

  • 1     REPORT DESCRIPTION
  • 2     INTRODUCTION
    • 2.1     Causes & Symptoms
    • 2.2     Diagnosis
    • 2.3     Classification
    • 2.4     Compensatory mechanisms
    • 2.5     Unmet needs
  • 3     EPIDEMIOLOGY
    • 3.1     Prevalence
    • 3.2     Incidence
    • 3.3     Hospitalizations
    • 3.4     Re-admissions
  • 4     MARKET DATA
    • 4.1     Forecasting model
    • 4.2     Market dynamics
    • 4.3     Market sizing
    • 4.4     Cost burden
  • 5     PIPELINE ANALYSIS
    • 5.1     Development stage
    • 5.2     Modalities
    • 5.3     Leading players
    • 5.4     Innovative approaches
    • 5.5     Associated targets
  • 6     GENETHERAPY
    • 6.1     Pipeline
    • 6.2     Competitive landscape
  • 7     STEMCELL THERAPY
    • 7.1     Pipeline
    • 7.2     Competitive landscape
    • 7.3     RNA BASED THERAPEUTICS
    • 7.4     mi-RNA
    • 7.5     m-RNA
    • 7.6     Pipeline
    • 7.7     Competitive landscape
  • 8     DRUGS (small molecules, recombinant proteins, growth factors)
    • 8.1     Pipeline
    • 8.2     Competitive landscape
  • 9     HOT TARGETS IN RESEARCH
  • 10     MAJOR PLAYERS
    • 10.1     Company Profiles
    • 10.2     Overview, Pipeline & Deals
  • 11     REFERENCES